Paving the road ahead for CD19 CAR T-cell therapy

Current Opinion in Hematology
Anandani Nellan, Daniel W Lee

Abstract

Modern immunotherapies, most notably in the form of anti-CD19 chimeric antigen receptor (CAR) T cells, have produced significant clinical responses in otherwise refractory pre-B-cell acute lymphoblastic leukemia patients. Several groups have simultaneously reported robust response rates in children and adults alike. These early studies indicate an impending shift in paradigm for the treatment of acute lymphoblastic leukemia. Incorporating CD19 CAR T-cell therapy into upfront or salvage regimens has its challenges and opportunities. Most CD19 CAR T-cell products in trial today are excellent at inducing minimal residual disease negative remissions, and most responding patients experience cytokine release syndrome and/or neurotoxicity. The challenges facing the CAR community involve how best to minimize the severity of cytokine release syndrome and neurotoxicity while maximizing antitumor efficacy, determining what role this therapy will play for the prophylaxis and treatment of central nervous system leukemia, and its implications on subsequent hematopoietic stem cell transplant given the emergence of CD19-negative relapses. CD19 CAR T-cell therapy is a powerful new tool in the oncologist's arsenal. How it is incorporated into st...Continue Reading

References

Feb 25, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard A MorganSteven A Rosenberg
Apr 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Renier BrentjensMichel Sadelain
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P HungerWilliam L Carroll
May 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniel W LeeStephan A Grupp
Feb 21, 2014·Science Translational Medicine·Marco L DavilaRenier Brentjens
Oct 16, 2014·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Jul 15, 2015·OncoTargets and Therapy·Josep-Maria RiberaEulàlia Genescà

❮ Previous
Next ❯

Citations

Aug 3, 2016·The Journal of Clinical Investigation·Partow KebriaeiLaurence J N Cooper
Apr 18, 2018·Oncotarget·Tiberiu TatLiren Qian
Oct 17, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xia XiaoMingfeng Zhao
Nov 20, 2021·Cancer Investigation·Wanying ZengShuang Liu

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Clinical Trials Mentioned

NCT01593696
NCT02315612

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.